Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction PRESS ...
- The breakthrough approval expands the existing indication of Jardiance ® to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that ...
In the phase III EMPEROR-Preserved trial, among nearly 6,000 patients with chronic HF with preserved ejection fraction (HFpEF), empagliflozin was able to slow kidney function decline over the 172-week ...
The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study. The Food and Drug Administration (FDA) has granted Fast ...
- Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. Jardiance is not ...
The double-blind EMPEROR-Reduced trial enrolled 3730 adults with HFrEF, with and without diabetes. Boehringer Ingelheim and Lilly announced positive topline results from a phase 3 trial evaluating the ...
RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) ...
Jardiance (empagliflozin; Boehringer Ingelheim and Lilly) The approval was based on data from the phase 3 EMPEROR-Preserved trial. The Food and Drug Administration (FDA) has approved Jardiance ® ...
- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40% 1 - ...
Jardiance is a diabetes medication that manages blood glucose levels, it is also used as a weight loss treatment. The active drug, Empagliflozin, although not technically a weight loss medication, ...
RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 26, 2014 /PRNewswire/ -- Jardiance ® (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, ...
- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback